– USA, MN – Humanetics Corporation, a clinical-stage pharmaceutical company pioneering radiation countermeasures, adjuvant oncology therapies, and pulmonary protective therapies for COVID-19, today announced the addition of Dr. Karen Smith (MD, Ph.D.) and Timothy Morris to its Board of Directors, adding significant experience in pharmaceutical leadership and drug development to the Board.
“We are thrilled to welcome Dr. Smith and Mr. Morris to the Humanetics Board of Directors,” said CEO, Ron Zenk. “It’s impossible to overstate the value that they will bring to our Board, particularly given the depth and breadth of their experience in biotech, healthcare, and drug development.”
About Dr. Karen Smith
Dr. Smith is a biotech/pharmaceutical executive and clinical/scientific advisor who holds an MD, Ph.D., MBA, and LLM and is sought after for her expertise in the U.S., Europe, Canada, and Australia. Her breadth of experience covers more than 100 clinical trials and 20+ major regulatory approvals in multiple jurisdictions, leading to product launches across a broad range of diverse therapeutic areas. Dr. Smith has held various President, CEO, Global Head of R&D, and Chief Medical Officer roles over the past 15 years. She has served on several boards with a history of successful corporate exits. She is currently a member of the board for Acceleron Pharmaceuticals, Sangamo Therapeutics, Antares Pharma, and Capstan Therapeutics.
“This is an exciting time at Humanetics, and I’m looking forward to being part of the team that’s poised to make an impactful difference in this urgent and unmet space,” commented Dr. Smith. “honored by the opportunity to serve on the Board and truly excited about the encouraging research surrounding BIO 300, as well as the widespread support among stakeholders, scientists, and government entities alike.”
About Timothy Morris
Timothy Morris is a seasoned biotech and finance executive known for completing more than 90 transactions at a combined value of over $5 billion. He currently serves as the COO and CFO of Humanigen, Inc. and has over 36 years of experience as a finance and biopharmaceutical executive, including 22 as CFO with public biopharmaceutical companies. He has raised more than $2 billion in equity and equity-like securities for seven companies and has been part of executive teams that were successful in the approval of three NDAs and one MAA.
About Humanetics Corporation
Humanetics is a clinical-stage pharmaceutical company engaged in the discovery, development, and commercialization of proprietary drugs to prevent severe tissue damage caused by exposure to radiation, viral infection, and other inflammatory diseases.
For more information: https://www.humaneticscorp.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.